0000891293-15-000071.txt : 20151223
0000891293-15-000071.hdr.sgml : 20151223
20151223185306
ACCESSION NUMBER: 0000891293-15-000071
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20151223
FILED AS OF DATE: 20151223
DATE AS OF CHANGE: 20151223
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CTI BIOPHARMA CORP
CENTRAL INDEX KEY: 0000891293
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911533912
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: 2062827100
MAIL ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 19960321
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SEELEY BRUCE J.
CENTRAL INDEX KEY: 0001474462
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12465
FILM NUMBER: 151306716
MAIL ADDRESS:
STREET 1: 21823 30TH DRIVE SE
CITY: BOTHELL
STATE: WA
ZIP: 98021
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2015-12-23
0
0000891293
CTI BIOPHARMA CORP
ctic
0001474462
SEELEY BRUCE J.
3101 WESTERN AVENUE
SUITE 600
SEATTLE
WA
98121
0
1
0
0
EVP, Chief Commercial Officer
Performance Rights
0
2015-12-23
4
D
0
406483
0
D
Common Stock
406483
0
D
Employee Stock Option (Right to Buy)
1.24
2015-12-23
4
A
0
1100000
0
A
2015-12-23
Common Stock
1100000
1100000
D
In a Form 4 filed on July 29, 2015, the reporting person reported the acquisition of the number of performance rights identified in the table above that related to the issuer's achievement of a market capitalization goal. That award no longer represents the right to receive shares of the issuer's common stock. Instead, if the applicable performance goal is achieved by December 31, 2016, the reporting person will be entitled to the grant of a stock option with respect to the same number of shares that would have been issued to the reporting person upon achievement of the goal under the original terms of the award.
The option is scheduled to vest in eight semi-annual installments over the four-year period following the grant date, subject to the reporting person's continued employment or service with the issuer through the applicable vesting date.
By: Louis A. Bianco, Attorney-in-fact For: Bruce J. Seeley
2015-12-23